Amicus Accounts Payable from 2010 to 2025

FOLD Stock  USD 8.63  0.06  0.69%   
Amicus Therapeutics' Accounts Payable is increasing over the years with stable fluctuation. Overall, Accounts Payable is expected to go to about 20.8 M this year. Accounts Payable is the amount Amicus Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Amicus Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2004-12-31
Previous Quarter
13.5 M
Current Value
12.9 M
Quarterly Volatility
20.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9 M, Interest Expense of 52.1 M or Other Operating Expenses of 528.6 M, as well as many indicators such as Price To Sales Ratio of 5.16, Dividend Yield of 0.0 or PTB Ratio of 15.52. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Latest Amicus Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Amicus Therapeutics over the last few years. An accounting item on the balance sheet that represents Amicus Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Amicus Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Amicus Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Pretty Stable
   Accounts Payable   
       Timeline  

Amicus Accounts Payable Regression Statistics

Arithmetic Mean24,978,648
Geometric Mean12,859,260
Coefficient Of Variation127.43
Mean Deviation20,883,757
Median16,345,000
Standard Deviation31,830,254
Sample Variance1013.2T
Range119.8M
R-Value0.21
Mean Square Error1035.5T
R-Squared0.05
Significance0.42
Slope1,434,729
Total Sum of Squares15197.5T

Amicus Accounts Payable History

202520.8 M
202412.9 M
202315.1 M
202215.4 M
202121.5 M
202017.1 M
2019120.4 M

About Amicus Therapeutics Financial Statements

Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable12.9 M20.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.18)
Revenue Per Share
1.736
Quarterly Revenue Growth
0.301
Return On Assets
0.0272
Return On Equity
(0.32)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.